BioNTech and BMS report 36.7% response rate for pumitamig in second-line lung cancer at ESMO

SentiSense · Published · Updated

BioNTech and Bristol Myers Squibb reported Phase 2 ROSETTA Lung-107 data at ESMO 2026: pumitamig plus docetaxel produced a 36.7% confirmed response ra...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis